secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0000950170-24-104915
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet prioritizes ADI-001 for autoimmunity; closes MCL enrollment; reports 80% ORR, 60% CR
--------------------------------------------------------------------------------

- Focuses ADI-001 development on four autoimmune indications: lupus nephritis, SLE, systemic sclerosis, ANCA vasculitis.
- Closed Phase 1 MCL enrollment; topline results: ORR 80% (8/10), CR 60% (6/10), median CR duration 17.5 months as of Aug 22, 2024.
- Patients heavily pretreated (median 3 prior therapies); 30% had progressed on prior CAR T; no GvHD, low grade ≥3 CRS/neurotoxicity.
- Plans to present translational data from Phase 1 NHL study at CAR-TCR Summit on Sept 19, 2024 in Boston.
- Expects to expand ADI-001 clinical development into additional autoimmune indications near term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024104915/0000950170-24-104915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024104915/acet-20240910.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-104915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer